Anal Cancer Screening Not Warranted in Men Who Have Sex with Men

(ChemotherapyAdvisor) – Anal human papillomavirus (HPV) and precursors of anal cancer are very common in men who have sex with men (MSM); however, a meta-analysis published in the Lancet Oncology online March 23 shows rate of progression to cancer is substantially lower than that for cervical precancerous lesions in women.

“Our findings mean that cervical cancer screening strategies cannot be simply extrapolated to anal cancer screening as current proposals suggest,” said Andrew Grulich, MBBS, MSc, PhD, University of New South Wales, Australia.

A systematic review and meta-analysis of 53 studies found that most men had anal HPV infection and high-grade anal intraepithelial neoplasia (AIN) was present in 20%–30%. Prevalence of infection with high-risk HPV types was substantially higher in HIV-positive men than in HIV negative men (73.5% vs. 37.2%), and precancerous abnormalities were also more common.

An estimated 10% of HIV-positive men develop high-grade AIN annually compared with about 3% of HIV-negative men. “These incidence rates seem to be higher than would be consistent with our estimate of the prevalence of high-grade AIN (29% in HIV-positive MSM and 21% in HIV-negative MSM), unless many of these high-grade lesions regress,” the authors noted.

In this study, the progression rate from high-grade AIN to anal cancer was approximately 1 in 600 per year in HIV-positive men and 1 in 4,000 per year in HIV-negative men. High-grade cervical cancer precursors have a much higher rate of progression to cervical cancer, about 1 in 80 annually.

“The identification of biomarkers to establish which men with high-grade AIN are at highest risk for progression to anal cancer, and which are likely to regress, should be a research priority,” they noted. “Large, good-quality prospective studies are needed to inform the development of anal cancer screening guidelines for MSM.”

Abstract

Podcast

Related Resources

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Gastrointestinal Cancers

Full-Spectrum Endoscopy Increases Polyp, Adenoma Detection

Full-Spectrum Endoscopy Increases Polyp, Adenoma Detection

Polyp and adenoma detection rates increased with lower miss rates when using full-spectrum endoscopy colonoscope instead of traditional forward-viewing colonoscope.

New Approaches to Liver Cancer Offering New Hope

New Approaches to Liver Cancer Offering New Hope

Recent research on liver cancer prevention and treatment is showing promise in combating the disease.

Trial of Vectibix vs Erbitux Meets Primary End Point for OS

Phase 3 trial evaluating Vectibix vs. Erbitux for the treatment of chemo-refractory metastatic colorectal cancer meets its primary endpoint for overall survival.